Eagle Bancorp, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 14% Upside

Eagle Bancorp's average price target increased from $32.17 to $32.5 by 6 analysts, with a range of $29 to $37. This implies a 14% upside from the Oct. 21 closing price. The consensus rating remains 'Buy' with 3 Buys, 3 Holds, and 0 Sells.

Original reporting
Published Oct 22, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 10:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eagle Bancorp, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 14% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

The modest price‑target increase may generate short‑term interest but is unlikely to drive a sustained rally.

02

Market read

Small‑cap bank receives a modest analyst upgrade; limited trading relevance.

03

What to watch

Potential credit‑quality concerns and macro‑rate environment could dampen upside.

Relevance 5/10Novelty 4/10Timing: today

Background

Eagle Bancorp is a community bank with a market cap under $500 M; analyst coverage is limited.

Market effects

Minor impact on regional bank sector; similar micro‑caps may see slight sentiment lift.

US small‑cap banking segment sees modest attention.

Limited; no broader market effect.

Counterpoint

The target raise may be overly optimistic given the bank's limited growth prospects.

Key entities

  • Eagle Bancorp, Inc.

    US‑listed community bank (ticker EBNC).

Related articles

$EGBNMed

Eagle Bancorp Q3 Earnings Call Highlights

Eagle Bancorp reported Q3 net interest margin at 2.60%, up 8 bps from Q2, with net interest income at $61.3M. Loans declined 0.9% to $6.6B, but management expects growth in Q4. Deposits shifted away from brokered funding, and expenses rose due to hiring. The company aims for loan growth mix of 40% C&I, 40% CRE, and 20% other. Capital ratios improved, with CET1 at 14.99%.

$EGBNMed

FOR EAGLE BANCORP, INC. IMMEDIATE RELEASE Second Quarter of 2026 Key Elements

EAGLE BANCORP INC (EGBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 final-2q2026egbnearnings.htm EX-99.2 final-2q2026egbnearnings 2nd Quarter 2026 Earnings Presentation EagleBankCorp.com July 22, 2026 Scan for digital version Date should be Earnings Release Date, not call date Do we change QR? Forward Looking Statements This presentatio

LowAI 8/10

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne – Thailand Business News

Ascletis Pharma Inc.'s partner, Sagimet Biosciences, has dosed the first patient in a Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial aims to enroll 800 patients. Ascletis' prior Phase III trial in China showed ASC40 was more effective than FDA-approved treatments, with 18.6% treatment success vs. 9.4% for sarecycline and 6.7% for doxycycline.